HK1211960A1 - Treating vascular disease and complications thereof - Google Patents

Treating vascular disease and complications thereof Download PDF

Info

Publication number
HK1211960A1
HK1211960A1 HK15112832.0A HK15112832A HK1211960A1 HK 1211960 A1 HK1211960 A1 HK 1211960A1 HK 15112832 A HK15112832 A HK 15112832A HK 1211960 A1 HK1211960 A1 HK 1211960A1
Authority
HK
Hong Kong
Prior art keywords
complications
vascular disease
treating vascular
chance
expected
Prior art date
Application number
HK15112832.0A
Other languages
English (en)
Chinese (zh)
Inventor
Simard John
Original Assignee
Xbiotech, Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xbiotech, Inc filed Critical Xbiotech, Inc
Publication of HK1211960A1 publication Critical patent/HK1211960A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/245IL-1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK15112832.0A 2012-10-04 2013-10-01 Treating vascular disease and complications thereof HK1211960A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261709754P 2012-10-04 2012-10-04
US201261709754P 2012-10-04
PCT/US2013/062903 WO2014055544A1 (en) 2012-10-04 2013-10-01 Treating vascular disease and complications thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
HK42020002705.0A Addition HK40012735A (en) 2012-10-04 2015-12-30 Treating vascular disease and complications thereof

Publications (1)

Publication Number Publication Date
HK1211960A1 true HK1211960A1 (en) 2016-06-03

Family

ID=50432830

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15112832.0A HK1211960A1 (en) 2012-10-04 2013-10-01 Treating vascular disease and complications thereof

Country Status (12)

Country Link
US (3) US20140099321A1 (https=)
EP (3) EP3524621A1 (https=)
JP (1) JP6460993B2 (https=)
KR (2) KR102296017B1 (https=)
CN (2) CN113018431A (https=)
AU (1) AU2013327501B2 (https=)
CA (1) CA2886747C (https=)
HK (1) HK1211960A1 (https=)
IL (1) IL237765B (https=)
MX (1) MX376241B (https=)
RU (1) RU2671955C2 (https=)
WO (1) WO2014055544A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102167261B1 (ko) 2010-06-18 2020-10-20 엑스바이오테크, 인크. 관절염 치료
US10294296B2 (en) 2010-08-23 2019-05-21 Xbiotech, Inc. Treatment for neoplastic diseases
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
ES2695102T3 (es) 2011-09-23 2019-01-02 Xbiotech Inc Tratamiento para la caquexia
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
CA3053231A1 (en) 2017-02-16 2018-08-23 Xbiotech Inc. Treatment of hidradenitis suppurativa
EP3965819A4 (en) * 2019-05-03 2023-07-12 University of Zürich TREATMENT OF CEREBRAL ISCHEMIA-REPERFUSION INJURY
CA3095740A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin alpha (il-1a)
CA3095675A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095676A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleukin 1 alpha (il-1a)
CA3095679A1 (en) 2020-10-07 2022-04-07 Xbiotech Inc. True human antibody specific for interleuken 1 alpha (il-1a)
KR102652849B1 (ko) 2022-03-14 2024-04-01 한국화학연구원 극성 아라미드 나노섬유로 제조한 하이드로겔

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
RU2235541C2 (ru) * 1994-10-04 2004-09-10 Эмори Юниверсити Лечение атеросклероза и других сердечно-сосудистых и воспалительных заболеваний
CA2374531A1 (en) * 1999-05-24 2000-11-30 Interleukin Genetics, Inc. Diagnostics and therapeutics for restenosis
WO2003018595A2 (en) * 2001-08-24 2003-03-06 Maine Medical Center Research Institute Copper-dependent non-traditional pro-inflammatory cytokine export and methods, compositions and kits relating thereto
US20040224893A1 (en) * 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
CA2726345C (en) * 2008-05-30 2018-08-28 John Simard Interleukin-1 alpha antibodies and methods of use
CA2763161A1 (en) * 2009-05-29 2010-12-02 Xoma Technology Ltd. Cardiovascular related uses of il-1.beta. antibodies and binding fragments thereof
JP5812669B2 (ja) 2011-04-27 2015-11-17 キヤノン株式会社 画像処理装置および画像処理方法およびコンピュータプログラム。

Also Published As

Publication number Publication date
CN104684929A (zh) 2015-06-03
MX376241B (es) 2025-03-06
MX2015004286A (es) 2015-08-06
EP2904010A1 (en) 2015-08-12
CA2886747A1 (en) 2014-04-10
KR20150063076A (ko) 2015-06-08
CA2886747C (en) 2023-12-05
EP2904010A4 (en) 2016-06-01
US20180057585A1 (en) 2018-03-01
EP3524621A1 (en) 2019-08-14
AU2013327501B2 (en) 2018-08-09
WO2014055544A1 (en) 2014-04-10
IL237765B (en) 2019-06-30
JP6460993B2 (ja) 2019-01-30
US20140099321A1 (en) 2014-04-10
IL237765A0 (en) 2015-05-31
AU2013327501A1 (en) 2015-04-02
KR20210108496A (ko) 2021-09-02
EP4628162A3 (en) 2025-12-03
RU2671955C2 (ru) 2018-11-08
EP4628162A2 (en) 2025-10-08
CN113018431A (zh) 2021-06-25
KR102429919B1 (ko) 2022-08-05
RU2015110635A (ru) 2016-11-27
JP2015531397A (ja) 2015-11-02
US20210403548A1 (en) 2021-12-30
KR102296017B1 (ko) 2021-09-01

Similar Documents

Publication Publication Date Title
HK1211960A1 (en) Treating vascular disease and complications thereof
JP2015531397A5 (https=)
WO2013079701A3 (en) Expression of mirnas in placental tissue
PH12013501790B1 (en) Use of dpp iv inhibitors
HK1200714A1 (en) Fgfr-binder-active agent conjugates
WO2012138913A3 (en) In vivo immunomagnetic hyperthermia platform for any cell or virus having a target surface receptor
WO2010144678A3 (en) Generation of vascularized human heart tissue and uses thereof
JOP20140344B1 (ar) تركيبات وطرق لتقليل المضاعفات السلبية العظمي للقلب والاوعية الدموية
MX2010006650A (es) Materiales y metodos para el tratamiento de proliferacion vascular ocular patologica.
WO2010102171A3 (en) Secreted ap2 and methods of inhibiting same
WO2014191738A8 (en) Degradable haemostat composition
WO2013165982A3 (en) Anti-human cytomegalvirus antibodies and use thereof
HRP20161147T1 (hr) Farmaceutski sastav i postupak njegove proizvodnje
WO2012106497A3 (en) Selection and treatment of subjects
Tebeu et al. Surgical outcome following treatment of obstetric vesicovaginal fistula among HIV-positive and HIV-negative patients in Cameroon
WO2019055776A3 (en) Compositions and methods for treatment of diseases involving cxcl1 function
HK1209041A1 (en) A method of weight reduction
Fukunaga et al. Chylous ascites as a rare complication after abdominal aortic aneurysm surgery
RU2010127731A (ru) Способ лечения гнойно-воспалительных осложнений у онкоурологических больных
WO2010093209A3 (ko) 안과 수술에 따른 상처 치유능 진단용 생물 표지자로서 카베올린-1의 용도 및 이를 이용한 상처 치유능 진단방법
张承磊 The treatment strategy of special distal landing zones in endovascular repair of abdominal aortic aneurysm
Liu et al. Preventive effects of modified chitosan medical anti-adhesion membrane on postoperative intra-abdominal adhesion
Mori Clinical guidelines for tuberculosis of Japan compared with those of other countries
Kanafyanova NEURONET PREDICTION OF VISION ORGAN TRAUMA SEVERITY
Parasuraman Pneumonitis and secondary pulmonary haemorrhage: case report